What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?

被引：0

作者：

Gomez-Martin, Maria ^{[1
,2
]}

Canfell, Oliver J. ^{[3
]}

Chai, Li Kheng ^{[4
]}

Jansson, Anna K. ^{[1
,2
]}

Littlewood, Robyn ^{[4
]}

Sullivan, Clair ^{[5
,6
]}

Power, Dawn ^{[7
]}

Clarke, Erin D. ^{[1
,2
]}

Ells, Louisa ^{[7
]}

De Vlieger, Nienke ^{[2
,8
]}

Burrows, Tracy L. ^{[1
,2
]}

Collins, Clare E. ^{[1
,2
]}

机构：

[1] Univ Newcastle, Coll Hlth Med & Wellbeing, Sch Hlth Sci, Callaghan, NSW 2308, Australia

[2] Hunter Med Res Inst, Food & Nutr Res Program, New Lambton Hts, NSW 2305, Australia

[3] Kings Coll London, Fac Life Sci & Med, Sch Life Course & Populat Sci, Dept Nutr Sci, London, England

[4] Queensland Govt, Hlth & Wellbeing Queensland, Brisbane, Qld, Australia

[5] Univ Queensland, Queensland Digital Hlth Ctr, Ctr Hlth Serv Res, St Lucia, Qld, Australia

[6] Queensland Hlth, Metro North Hosp & Hlth Serv, Herston, Qld, Australia

[7] Leeds Beckett Univ, Obes Inst, Sch Hlth, Leeds, England

[8] Univ Newcastle, Coll Engn Sci & Environm, Sch Environm & Life Sci, Ourimbah, NSW 2258, Australia

来源：

CURRENT OBESITY REPORTS | 2025年 / 14卷 / 01期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Obesity; Primary prevention; Anti-obesity medication; Glucagon-like peptide-1 agonists; Clinical obesity; GLP-1/GIP; Diet; Nutrition; NONCOMMUNICABLE DISEASES; BODY-WEIGHT; 3.0; MG; ADULTS; LIRAGLUTIDE; INTERVENTIONS; MANAGEMENT; DIETS; METAANALYSIS; OVERWEIGHT;

D O I：

10.1007/s13679-025-00632-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review To examine the evidence and continuing role of strategies for the primary prevention and treatment of obesity in the context of effective obesity pharmacotherapies, through a narrative review. Recent findings Global policies to improve nutritional labelling and reduce sugar-sweetened beverages consumption have been implemented worldwide (> 45 countries) with some success which varies by population and environment. Tailored behavioural interventions are effective and essential to reduce individual risk of progression from preclinical to clinical obesity. Pharmacotherapies are powerful treatment agents for clinical obesity but must consider nutritional and metabolic risks of use and discontinuation. The obesogenic environment continues to undermine individual agency to adopt healthier dietary and physical activity patterns. Population health informatics tools could inform tailored interventions based on real-time risk and contribute to obesity prevention and treatment. Summary Efforts to rebalance investment towards obesity prevention must continue to improve population health and reduce healthcare burden.

引用

页数：14

共 125 条

[1]

Administration FD, 2023, FDA Approves new medication for chronic weight management

[2]

Administration USFaD, 2021, FDA Approves new drug treatment for chronic weight management, first since 2014

[3] Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of the WRAP randomised controlled trial [J].

Ahern, Amy L. ;

Breeze, Penny ;

Fusco, Francesco ;

Sharp, Stephen J. ;

Islam, Nazrul ;

Wheeler, Graham M. ;

Hill, Andrew J. ;

Hughes, Carly A. ;

Duschinsky, Robbie ;

Thomas, Chloe ;

Bates, Sarah ;

Woolston, Jenny ;

Stubbings, Marie ;

Whittle, Fiona ;

Boothby, Clare ;

Bostock, Jennifer ;

Jebb, Susan ;

Aveyard, Paul ;

Boyland, Emma ;

Halford, Jason C. G. ;

Morris, Stephen ;

Brennan, Alan ;

Griffin, Simon J. .

LANCET PUBLIC HEALTH, 2022, 7 (10) :E866-E875

[4] The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis [J].

Alexander, Jason T. ;

Staab, Erin M. ;

Wan, Wen ;

Franco, Melissa ;

Knitter, Alexandra ;

Skandari, M. Reza ;

Bolen, Shari ;

Maruthur, Nisa M. ;

Huang, Elbert S. ;

Philipson, Louis H. ;

Winn, Aaron N. ;

Thomas, Celeste C. ;

Zeytinoglu, Meltem ;

Press, Valerie G. ;

Tung, Elizabeth L. ;

Gunter, Kathryn ;

Bindon, Brittany ;

Jumani, Sanjay ;

Laiteerapong, Neda .

JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (02) :415-438

[5] Evaluation of research on interventions aligned to WHO 'Best Buys' for NCDs in low-income and lower-middle-income countries: a systematic review from 1990 to 2015 [J].

Allen, Luke N. ;

Pullar, Jessica ;

Wickramasinghe, Kremlin Khamarj ;

Williams, Julianne ;

Roberts, Nia ;

Mikkelsen, Bente ;

Varghese, Cherian ;

Townsend, Nick .

BMJ GLOBAL HEALTH, 2018, 3 (01)

[6] A systematic review of diabetes prevention programs adapted to include family members [J].

Andreae, Susan J. ;

Reeves, Hailey ;

Casey, Thomas ;

Lindberg, Anna ;

Pickett, Kristen A. .

PREVENTIVE MEDICINE REPORTS, 2024, 39

[7]

[Anonymous], 2024, Obesity and overweight

[8] The Effects of Very Low Energy Diets and Low Energy Diets with Exercise Training on Skeletal Muscle Mass: A Narrative Review [J].

Ardavani, Arash ;

Aziz, Hariz ;

Smith, Ken ;

Atherton, Philip J. ;

Phillips, Bethan E. ;

Idris, Iskandar .

ADVANCES IN THERAPY, 2021, 38 (01) :149-163

[9] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity [J].

Aronne, Louis J. ;

Sattar, Naveed ;

Horn, Deborah B. ;

Bays, Harold E. ;

Wharton, Sean ;

Lin, Wen-Yuan ;

Ahmad, Nadia N. ;

Zhang, Shuyu ;

Liao, Ran ;

Bunck, Mathijs C. ;

Jouravskaya, Irina ;

Murphy, Madhumita A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (01) :38-48

[10] Advancing precision public health for obesity in children [J].

Baker, Jennifer L. ;

Bjerregaard, Lise G. .

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2023, 24 (05) :1003-1010

← 1 2 3 4 5 6 7 8 9 10 →